Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current revenue (TTM ) is S$50.17 Billion. In 2023 the company made a revenue of S$44.65 Billion an increase over the revenue in the year 2022 that were of S$33.58 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.